Recently, anoctamin-2 has been proposed as an autoimmune target in MS with antibody response associated with higher MS risk, along with cross-reactivity to specific peptides of EBNA-1.30 Finally, the sequence homology between EBNA-1 and GlialCAM has shown potent immune reactivity in MS.32 While the steady increase in MS risk related to EBNA-1 antibody levels is consistent with a direct pathological role of that immunity with the multitude of potential mimicry epitopes, the degree and extent of molecular mimicry in vivo for MS pathogenesis remain to be firmly defined. Here, HEPACAM is linked to myeloid sarcoma.